Scimitar Equity Research Issues Review on Matritech, Inc.
BOSTON, May 5 /PRNewswire-FirstCall/ -- Scimitar Equity Research, Inc. issues
a review on Matritech, Inc. (AMEX:MZT) entitled "A Faster, Cheaper and More
Reliable Test to Detect Bladder Cancer." The analyst research review is
available on Scimitar's website; http://www.scimitarequity.com/.
Scimitar Equity Research, Inc. provides sponsored equity research of the health
sciences industry for the institutional and investment communities. We certify
that all the views expressed in this review, accurately reflect our personal
views about MZT (AMEX) and its or their securities. No part of our compensation
was, is, or will be, directly or indirectly, related to the specific
recommendations or views contained in this review and we will not have any
investment banking relationships or personal investment in any sponsored
company. Investors are advised that this analysis and review is issued solely
for informational purposes and is not to be construed as an offer to sell or
the solicitation of an offer to buy. Scimitar was paid for preparing this
review. This analysis and review does not have regard to the specific
investment objectives, financial situation and the information contained herein
is based on sources that we believe to be reliable but is not guaranteed by us
as being accurate and does not purport to be a complete statement or summary of
the available data. Any opinions expressed are statements of our own judgment
as of the date of publication and are subject to change without notice. Please
read all our important disclosures.
CONTACT:
Scimitar Equity Research, Inc. Henry W. McCusker
Director of Research
phone: (617) 236-6396
fax: (617) 236-6397
e-mail: DATASOURCE: Scimitar Equity Research, Inc.
CONTACT: Henry W. McCusker, Director of Research for Scimitar Equity Research, Inc., +1-617-236-6396, Web site: http://www.scimitarequity.com/
|